Sakar Healthcare anticipates significant expansion in fiscal year 2027, largely due to increased export sales. The company also expects growing oncology patient numbers to bolster their growth trajectory.

Sakar Healthcare Limited experienced a 20% surge in share price today due to impressive fiscal year 2026 results showing profit doubling and revenue growth of 41%. This growth can be attributed to effective debt reduction, strong cash flows, and increased EPS, indicative of financial discipline and operational efficiency.

Sakar Healthcare reports a significant 67% year-on-year increase in Q4 EBITDA, with the figure reaching ₹262 million. This growth has led to an improvement in the company's earnings margin, which now stands at 36.9%.